Cost considerations in the management of atrial fibrillation – impact of dronedarone

References

• CammAJObelOAEpidemiology and mechanism of atrial fibrillation and atrial flutterAm J Cardiol1996788A3118903269
   PubMedGoogle Scholar
• NaccarelliGVVarkerHLinJSchulmanKLIncreasing prevalence of atrial fibrillation and flutter in the United StatesAm J Cardiol2009104111534153919932788
   PubMed Web of Science ®Google Scholar
• GoASHylekEMPhillipsKAPrevalence of diagnosed atrial f ibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) StudyJAMA2001285182370237511343485
   PubMed Web of Science ®Google Scholar
• BialyDLehmannMHSchumacherDNSteinmanRTMeissnerMDHospitalization for arrhythmias in the United States: importance of atrial fibrillationJ Am Coll Cardiol199219341A
   Google Scholar
• OlivottoICecchiFCaseySADolaraATraverseJHMaronBJImpact of atrial fibrillation on the clinical course of hypertrophic cardiomyopathyCirculation2001104212517252411714644
   PubMed Web of Science ®Google Scholar
• WolfPAMitchellJBBakerCSKannelWBD’AgostinoRBImpact of atrial fibrillation on mortality, stroke, and medical costsArch Intern Med199815832292349472202
   PubMedGoogle Scholar
• OlesenJBLipGYHansenMLValidation of risk stratification schemes for predicting stroke and thromboembolism in patients with atrial fibrillation: nationwide cohort studyBMJ2011342d12421282258
   PubMed Web of Science ®Google Scholar
• BenjaminEJWolfPAD’AgostinoRBSilbershatzHKannelWBLevyDImpact of atrial fibrillation on the risk of death: the Framingham Heart StudyCirculation199898109469529737513
   PubMed Web of Science ®Google Scholar
• RingborgANieuwlaatRLindgrenPCosts of atrial fibrillation in five European countries: results from the Euro Heart Survey on atrial fibrillationEuropace200810440341118326853
   PubMed Web of Science ®Google Scholar
• ChungMKShemanskiLShermanDGFunctional status in rate-versus rhythm-control strategies for atrial fibrillation: results of the Atrial Fibrillation Follow-Up Investigation of Rhythm Management (AFFIRM) Functional Status SubstudyJ Am Coll Cardiol200546101891189916286177
   PubMed Web of Science ®Google Scholar
• CorleySDEpsteinAEDiMarcoJPRelationships between sinus rhythm, treatment, and survival in the Atrial Fibrillation Follow-Up Investigation of Rhythm Management (AFFIRM) StudyCirculation2004109121509151315007003
   PubMed Web of Science ®Google Scholar
• GuglinMChenRCurtisABSinus rhythm is associated with fewer heart failure symptoms: insights from the AFFIRM trialHeart Rhythm20107559660120159046
   PubMed Web of Science ®Google Scholar
• RoyDTalajicMDorianPAmiodarone to prevent recurrence of atrial fibrillation. Canadian Trial of Atrial Fibrillation InvestigatorsN Engl J Med20003421391392010738049
   PubMed Web of Science ®Google Scholar
• VassalloPTrohmanRGPrescribing amiodarone: an evidence-based review of clinical indicationsJAMA2007298111312132217878423
   PubMed Web of Science ®Google Scholar
• NattelSSinghBNEvolution, mechanisms, and classification of antiarrhythmic drugs: focus on class III actionsAm J Cardiol1999849A11R19R
   PubMed Web of Science ®Google Scholar
• WilberDJPapponeCNeuzilPComparison of antiarrhythmic drug therapy and radiofrequency catheter ablation in patients with paroxysmal atrial fibrillation: a randomized controlled trialJAMA2010303433334020103757
   PubMed Web of Science ®Google Scholar
• CappatoRCalkinsHChenSAUpdated worldwide survey on the methods, efficacy, and safety of catheter ablation for human atrial fibrillationCirc Arrhythm Electrophysiol201031323819995881
   PubMed Web of Science ®Google Scholar
• Van GelderICGroenveldHFCrijnsHJLenient versus strict rate control in patients with atrial fibrillationN Engl J Med2010362151363137320231232
   PubMed Web of Science ®Google Scholar
• GillisAMVermaATalajicMNattelSDorianPCanadian Cardiovascular Society atrial fibrillation guidelines 2010: rate and rhythm managementCan J Cardiol2011271475921329862
   PubMed Web of Science ®Google Scholar
• StewartSMurphyNFWalkerAMcGuireAMcMurrayJJCost of an emerging epidemic: an economic analysis of atrial fibrillation in the UKHeart200490328629214966048
   PubMed Web of Science ®Google Scholar
• HartRGPearceLAAguilarMIMeta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillationAnn Intern Med20071461285786717577005
   PubMed Web of Science ®Google Scholar
• ACTIVE InvestigatorsConnollySJPogueJHartRGEffect of clopidogrel added to aspirin in patients with atrial fibrillationN Engl J Med2009360202066207819336502
   PubMed Web of Science ®Google Scholar
• ConnollySJEzekowitzMDYusufSDabigatran versus warfarin in patients with atrial fibrillationN Engl J Med2009361121139115119717844
   PubMed Web of Science ®Google Scholar
• BlackshearJLOdellJAAppendage obliteration to reduce stroke in cardiac surgical patients with atrial fibrillationAnn Thorac Surg19966127557598572814
   PubMed Web of Science ®Google Scholar
• ReddyVYHolmesDDoshiSKNeuzilPKarSSafety of percutaneous left atrial appendage closure: results from the Watchman Left Atrial Appendage System for Embolic Protection in Patients with AF (PROTECT AF) clinical trial and the Continued Access RegistryCirculation2011123441742421242484
   PubMed Web of Science ®Google Scholar
• CoyneKSParamoreCGrandySMercaderMReynoldsMZimetbaumPAssessing the direct costs of treating nonvalvular atrial fibrillation in the United StatesValue Health20069534835616961553
   PubMed Web of Science ®Google Scholar
• BruggenjurgenBRossnagelKRollSThe impact of atrial fibrillation on the cost of stroke: the berlin acute stroke studyValue Health200710213714317391422
   PubMed Web of Science ®Google Scholar
• Canadian Institute for Health InformationThe Cost of Acute Care Hospital Stays by Medical Condition in Canada, 2004–2005 Available from: http://secure.cihi.ca/cihiweb/products/nhex_acutecare07_e.pdfAccessed December 29, 2011
   Google Scholar
• WuEQBirnbaumHGMarevaMEconomic burden and co-morbidities of atrial fibrillation in a privately insured populationCurr Med Res Opin200521101693169916238910
   PubMed Web of Science ®Google Scholar
• NaccarelliGVJohnstonSSLinJPatelPPSchulmanKLCost burden of cardiovascular hospitalization and mortality in ATHENA-like patients with atrial fibrillation/atrial flutter in the United StatesClin Cardiol201033527027920513065
   PubMed Web of Science ®Google Scholar
• ReinholdTLindigCWillichSNBruggenjurgenBThe costs of atrial fibrillation in patients with cardiovascular comorbidities – a longitudinal analysis of German health insurance dataEuropace20111391275128021515590
   PubMed Web of Science ®Google Scholar
• HolstensonERingborgALindgrenPPredictors of costs related to cardiovascular disease among patients with atrial fibrillation in five European countriesEuropace2011131233020823043
   PubMed Web of Science ®Google Scholar
• KhaykinYMorilloCASkanesACMcCrackenAHumphriesKKerrCRCost comparison of catheter ablation and medical therapy in atrial fibrillationJ Cardiovasc Electrophysiol200718990791317666065
   PubMed Web of Science ®Google Scholar
• MoeremansKAliottEChillouCdAnnemansLPenCLJongPdSecond line pharmacological management of paroxysmal and persistent atrial fibrillation in france: a cost analysisValue Health20003640741616464200
   PubMedGoogle Scholar
• GladstoneDJBuiEFangJPotentially preventable strokes in high-risk patients with atrial fibrillation who are not adequately anti-coagulatedStroke200940123524018757287
   PubMed Web of Science ®Google Scholar
• GrangerCBAlexanderJHMcMurrayJJApixaban versus warfarin in patients with atrial fibrillationN Engl J Med20113651198199221870978
   PubMed Web of Science ®Google Scholar
• SorensenSVKansalARConnollySCost-effectiveness of dabigatran etexilate for the prevention of stroke and systemic embolism in atrial fibrillation: a Canadian payer perspectiveThromb Haemost2011105590891921431243
   PubMed Web of Science ®Google Scholar
• PinkJLaneSPirmohamedMHughesDADabigatran etexilate versus warfarin in management of non-valvular atrial fibrillation in UK context: quantitative benefit-harm and economic analysesBMJ2011343d633322042753
   PubMed Web of Science ®Google Scholar
• ShahSVGageBFCost-effectiveness of dabigatran for stroke prophylaxis in atrial fibrillationCirculation2011123222562257021606397
   PubMed Web of Science ®Google Scholar
• HaissaguerreMJaisPShahDCSpontaneous initiation of atrial fibrillation by ectopic beats originating in the pulmonary veinsN Engl J Med1998339106596669725923
   PubMed Web of Science ®Google Scholar
• NademaneeKMcKenzieJKosarEA new approach for catheter ablation of atrial fibrillation: mapping of the electrophysiologic substrateJ Am Coll Cardiol200443112044205315172410
   PubMed Web of Science ®Google Scholar
• NakagawaHScherlagBJPattersonEIkedaALockwoodDJackmanWMPathophysiologic basis of autonomic ganglionated plexus ablation in patients with atrial fibrillationHeart Rhythm2009612 SupplS26S3419959140
   PubMed Web of Science ®Google Scholar
• WazniOMMarroucheNFMartinDORadiofrequency ablation vs antiarrhythmic drugs as first-line treatment of symptomatic atrial fibrillation: a randomized trialJAMA2005293212634264015928285
   PubMed Web of Science ®Google Scholar
• JaisPCauchemezBMacleLCatheter ablation versus anti-arrhythmic drugs for atrial fibrillation: the A4 studyCirculation2008118242498250519029470
   PubMed Web of Science ®Google Scholar
• ReynoldsMREssebagVZimetbaumPCohenDJHealthcare resource utilization and costs associated with recurrent episodes of atrial fibrillation: the FRACTAL registryJ Cardiovasc Electrophysiol200718662863317451468
   PubMed Web of Science ®Google Scholar
• ChanPSVijanSMoradyFOralHCost-effectiveness of radiofrequency catheter ablation for atrial fibrillationJ Am Coll Cardiol200647122513252016781382
   PubMed Web of Science ®Google Scholar
• EckardNDavidsonTWalfridssonHLevinALCost-effectiveness of catheter ablation treatment for patients with symptomatic atrial fibrillationJ Atr Fibrillation200918461470
   Google Scholar
• McKennaCPalmerSRodgersMCost-effectiveness of radiofrequency catheter ablation for the treatment of atrial fibrillation in the United KingdomHeart200995754254919095714
   PubMed Web of Science ®Google Scholar
• ReynoldsMRZimetbaumPJosephsonMEEllisEDanilovTCohenDJCost-effectiveness of radiofrequency catheter ablation compared with antiarrhythmic drug therapy for paroxysmal atrial fibrillationCirc Arrhythm Electrophysiol20092436236919808491
   PubMed Web of Science ®Google Scholar
• KathoferSThomasDKarleCAThe novel antiarrhythmic drug dronedarone: comparison with amiodaroneCardiovasc Drug Rev200523321723016252015
   PubMed Web of Science ®Google Scholar
• DavyJMHeroldMHoglundCDronedarone for the control of ventricular rate in permanent atrial fibrillation: the Efficacy and safety of dRonedArone for the cOntrol of ventricular rate during atrial fibrillation (ERATO) studyAm Heart J20081563527e521e52918760136
   PubMed Web of Science ®Google Scholar
• HohnloserSHCrijnsHJvan EickelsMEffect of drone-darone on cardiovascular events in atrial fibrillationN Engl J Med2009360766867819213680
   PubMed Web of Science ®Google Scholar
• Torp-PedersenCCrijnsHJGaudinCPageRLConnollySJHohnloserSHATHENA InvestigatorsImpact of dronedarone on hospitalization burden in patients with atrial fibrillation: results from the ATHENA studyEuropace20111381118112621576129
   PubMed Web of Science ®Google Scholar
• NHS National Institute for Health and Clinical ExcellenceDronedarone for the treatment of nonpermanent atrial fibrillation (TA197)2010 Available from: http://publications.nice.org.uk/dronedarone-for-the-treatment-of-nonpermanent-atrial-fibrillation-ta197/guidanceAccessed December 10, 2011
   Google Scholar
• KoberLTorp-PedersenCMcMurrayJJIncreased mortality after dronedarone therapy for severe heart failureN Engl J Med2008358252678268718565860
   PubMed Web of Science ®Google Scholar
• FDAFDA Drug Safety Communication: Multaq (dronedarone) and increased risk of death and serious cardiovascular adverse events2011 Available from: http://www.fda.gov/Drugs/DrugSafety/ucm264059.htmAccessed November 2, 2011
   Google Scholar
• FDAFDA Drug Safety Communication: Severe liver injury associated with the use of dronedarone (marketed as Multaq)2011 Available from: http://www.fda.gov/drugs/drugsafety/ucm240011.htmAccessed November 2, 2011
   Google Scholar
• PicciniJPHasselbladVPetersonEDWashamJBCaliffRMKongDFComparative efficacy of dronedarone and amiodarone for the maintenance of sinus rhythm in patients with atrial fibrillationJ Am Coll Cardiol200954121089109519744618
   PubMed Web of Science ®Google Scholar
• Le HeuzeyJYDe FerrariGMRadzikDSantiniMZhuJDavyJMA short-term, randomized, double-blind, parallel-group study to evaluate the efficacy and safety of dronedarone versus amiodarone in patients with persistent atrial fibrillation: the DIONYSOS studyJ Cardiovasc Electrophysiol201021659760520384650
   PubMed Web of Science ®Google Scholar
• Canadian Agency for Drugs and Technologies in HealthCEDAC FINAL RECOMMENDATION on DRONEDARONE HYDROCHLORIDECommon Drug Review2010 Available from: http://www.cadth.ca/media/cdr/complete/cdr_complete_Multaq_May-31-2010.pdfAccessed December 10, 2011
   Google Scholar
• SaksenaSSleeAWaldoALCardiovascular outcomes in the AFFIRM Trial (Atrial Fibrillation Follow-Up Investigation of Rhythm Management). An assessment of individual antiarrhythmic drug therapies compared with rate control with propensity score-matched analysesJ Am Coll Cardiol201158191975198522032709
   PubMed Web of Science ®Google Scholar
• TouboulPBrugadaJCapucciACrijnsHJEdvardssonNHohnloserSHDronedarone for prevention of atrial fibrillation: a dose-ranging studyEur Heart J200324161481148712919771
   PubMed Web of Science ®Google Scholar
• KoberLTorp-PedersenCMcMurrayJJIncreased mortality after dronedarone therapy for severe heart failureN Engl J Med2008358252678268718565860
   PubMed Web of Science ®Google Scholar
• SinghBNConnollySJCrijnsHJDronedarone for maintenance of sinus rhythm in atrial fibrillation or flutterN Engl J Med20073571098799917804843
   PubMed Web of Science ®Google Scholar